Latest news

Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a new customer in China. The customer is a large pharmaceutical manufacturer, and the order relates to evaluation of NLAB Saga® on a production scale. The order, which is worth USD 180,000, will be delivered during the second quarter. ”This is a highly interesting customer for us as it is larger than some of the others we work with. Among other

FINANCIAL SUMMARY Net sales for the first quarter amounted to SEK 10,751 thousand (5,037) The operating loss amounted to SEK 9,241 thousand (15,331) Loss after tax amounted to SEK 10,171 thousand (16,734) Earnings per share before and after dilution were SEK -0.12 (-0.46) Cash and cash equivalents per 31 March 2024 amounted to SEK 28,348 thousand (23,600). Shortly after the end of the quarter, the company’s cash and cash equivalents increased by approximately SEK 7

The Annual Report for 2024 is now available Annual Report 2024 Nanologica AB (publ)

FINANCIAL SUMMARY • Net sales for the fourth quarter amounted to SEK 6,715 thousand (75) and for the full year to SEK 14,538 thousand (1,443) • Operating loss for the quarter amounted to SEK -11,890 thousand (-35,638) and for the full year to SEK -59,255 thousand (-69,963). For the full year, operating profit was affected by write-downs of tangible and intangible assets totaling SEK 10,434 thousand (14,523). • Loss after tax for the quarter amounted